Latest News
Per Norlén joins Strike Pharma as new CEO
Strike Pharma, (“Strike”) a Swedish biotech with a novel technology for antibody-drug conjugation, has announced the appointment of Dr Per Norlén, MD PhD, as new CEO. Dr Norlén brings more than 20 years of clinical and commercial experience from leading positions within big pharma and biotech.
Strike Pharma granted patent to protect core technology
Strike Pharma has been granted a patent in Japan (JP 2021-529122), protecting the company’s core ADAC technology
Strike Pharma receives funding from BIO-X Accelerate program
The project is financed by the European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS program BIO-X Accelerate
Strike Pharma presents further developments at CICON23
Scientists from Strike Pharma presented two scientific posters demonstrating progress in the preclinical development of STRIKE2001-KRAS and in the use of the ADAC technology platform for drug cargo delivery.
Strike Pharma and FyoniBio conclude successful cell line development of Strike’s bi-specific antibody and clinical lead candidate
FyoniBio to present data at PEGS Boston 2023
Strike Pharma presents latest developments at AACR 2023
Chief Scientific Officer, Associate Professor Sara Mangsbo, presented some of the latest data demonstrating progress in the development of the ADAC technology platform for precision cancer immunotherapy.
Funds awarded to study ADAC™ technology in depth
Research to be supported by Cancerfonden, one of Sweden’s largest financiers of cancer research
Strike Pharma continues expansion of management team
Joacim Elmén appointed as Director, CMC
Strike Pharma and FyoniBio sign Master Service Agreement
Agreement covers Cell Line Development for a novel bi-specific therapeutic mAb
Strike Pharma’s Chief Scientific Officer receives BiotechBuilders Award 2022
Dr. Sara Mangsbo acknowledged for entrepreneurship and her contribution to Swedish life science industry